Portfolio

Fastinov
Biotechnology
EGF II | EGF III | EGF IV

Invested in
2022

INVESTMENT RATIONALE

Development of differentiating technology to fight against antimicrobial resistance.

STRATEGY

Support solution development and go-to-market strategy